Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

Alvarez Guisasola, 2008, Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study., Diabetes Obes Metab, 10, 8, 10.1111/j.1463-1326.2008.00881.x

Harris, 2005, Glycemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study)., Diabetes Res Clin Pract, 70, 90, 10.1016/j.diabres.2005.03.024

Hoerger, 2008, Is glycemic control improving in U.S. adults?, Diabetes Care, 31, 81, 10.2337/dc07-1572

Liebl, 2002, Evaluation of risk factors for development of complications in type II diabetes in Europe., Diabetologia, 45, S23, 10.1007/s00125-002-0863-0

Tang, 2003, The financing burden of treatment of diabetes-II and its symptom in urban China., Chin Health Econ, 12, 21

Defronzo, 2009, Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus., Diabetes, 58, 773, 10.2337/db09-9028

Wright, 2007, Active sugar transport in health and disease., J Intern Med, 261, 32, 10.1111/j.1365-2796.2006.01746.x

Hummel, 2011, Glucose transport by human renal Na+/d-glucose cotransporters SGLT1 and SGLT2., Am J Physiol Cell Physiol, 300, C14, 10.1152/ajpcell.00388.2010

Nair, 2010, Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus., J Clin Endocrinol Metab, 95, 34, 10.1210/jc.2009-0473

Meng, 2008, Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes., J Med Chem, 51, 1145, 10.1021/jm701272q

Ferrannini, 2010, Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial., Diabetes Care, 33, 2217, 10.2337/dc10-0612

Bailey, 2010, Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial., Lancet, 375, 2223, 10.1016/S0140-6736(10)60407-2

Strojek, 2011, Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomised, 24-week, double-blind, placebo-controlled trial., Diabetes Obes Metab, 13, 928, 10.1111/j.1463-1326.2011.01434.x

Wilding, 2009, A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment., Diabetes Care, 32, 1656, 10.2337/dc09-0517

Cockcroft, 1976, Prediction of creatinine clearance from serum creatinine., Nephron, 16, 31, 10.1159/000180580

Jendle, 2009, Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue., Diabetes Obes Metab, 11, 1163, 10.1111/j.1463-1326.2009.01158.x

Albanese, 2003, Clinical applications of body composition measurements using DXA., J Clin Densitom, 6, 75, 10.1385/JCD:6:2:75

Andreoli, 2009, Body composition assessment by dual-energy x-ray absorptiometry (DXA)., Radiol Med, 114, 286, 10.1007/s11547-009-0369-7

Kullberg, 2009, Reproducibility of hepatic triglyceride content assessment in normals using localized magnetic resonance spectroscopy., Diabetes Obes Metab, 11, 516, 10.1111/j.1463-1326.2008.00979.x

Hochberg, 1988, A sharper Bonferroni procedure for multiple tests of significance., Biometrika, 75, 800, 10.1093/biomet/75.4.800

Zhang, 2008, Improving efficiency of inferences in randomized clinical trials using auxiliary covariates., Biometrics, 64, 707, 10.1111/j.1541-0420.2007.00976.x

Kasichayanula, 2011, Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects., Diabetes Obes Metab, 13, 47, 10.1111/j.1463-1326.2010.01314.x

National Research Council, 2010, The prevention and treatment of missing data in clinical trials. Panel on Handling Missing Data in Clinical Trials, Committee on National Statistics (CNSTAT), Division of Behavioral and Social Sciences and Education

Norris, 2004, Long-term effectiveness of lifestyle and behavioral weight loss interventions in adults with type 2 diabetes: a meta-analysis., Am J Med, 117, 762, 10.1016/j.amjmed.2004.05.024

Freemantle, 2008, How strong is the association between abdominal obesity and the incidence of type 2 diabetes?, Int J Clin Pract, 62, 1391, 10.1111/j.1742-1241.2008.01805.x

Gastaldelli, 2007, Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects., Gastroenterology, 133, 496, 10.1053/j.gastro.2007.04.068

Grundy, 2008, Metabolic syndrome pandemic., Arterioscler Thromb Vasc Biol, 28, 629, 10.1161/ATVBAHA.107.151092

de Koning, 2007, Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies., Eur Heart J, 28, 850, 10.1093/eurheartj/ehm026

Bays, 2011, Adiposopathy is “sick fat” a cardiovascular disease?, J Am Coll Cardiol, 57, 2461, 10.1016/j.jacc.2011.02.038

Hermansen, 2007, Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus., Drug Saf, 30, 1127, 10.2165/00002018-200730120-00005

Wilding, 2011, Glucagon-like peptide-1 analogues for type 2 diabetes., BMJ, 342, d410, 10.1136/bmj.d410

Basu, 2006, Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes., Diabetes Care, 29, 510, 10.2337/diacare.29.03.06.dc05-2004

Carey, 2002, Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected], Obes Res, 10, 1008, 10.1038/oby.2002.137

Smith, 2005, Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial., Metabolism, 54, 24, 10.1016/j.metabol.2004.07.008

Bunck, 2010, Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition., Diabetes Care, 33, 1734, 10.2337/dc09-2361

Gallwitz, 2010, Changes in body composition after 9 months of treatment with exenatide twice daily versus glimepiride: comment letter on Jendle et al., Diabetes Obes Metab, 12, 1127, 10.1111/j.1463-1326.2010.01309.x

Harder, 2004, The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes., Diabetes Care, 27, 1915, 10.2337/diacare.27.8.1915